Telix Pharmaceuticals Stock Rallies on Clinical Trial Success and FDA Progress

Telix Pharmaceuticals shares surged after completing pivotal clinical trials and advancing its regulatory pathway. The positive data prompted H.C. Wainwright to reaffirm buy ratings on Telix and highlight similar catalysts for peer biotechs like BridgeBio and Alnylam.